Changes in Testing and Treatment Methods in Osteoporosis Care

Table 3

Postmatching test items, prescription details, and knowledge acquisition methods.

		2015	2020	value
The number of doctors extracted		74	74
Examination Items	Xp of the thoracolumbar spine (%)	45 (60.8)	38 (51.4)	0.25
	Bone mineral density of the lumbar spine and hip joint (%)	30 (40.5)	47 (63.5)
	MRI of spine (%)	4 (5.4)	2 (2.7)	0.40
	No further examination (%)	15 (20.3)	8 (10.8)	0.11
Breakdown of bone metabolic markers	Any bone metabolic markers (%)	59 (79.7)	60 (81.1)	0.84
	Urinary NTX (%)	22 (29.7)	9 (12.2)
	Serum NTX (%)	4 (5.4)	12 (16.2)
	BAP (%)	12 (16.2)	11 (14.9)	0.82
	P1NP (%)	23 (31.1)	44 (59.5)
	TRACP-5b (%)	33 (44.6)	52 (70.3)
	ucOC (%)	1 (1.4)	3 (4.1)	0.31
	DPD (%)	0 (0)	0 (0)	1.00
Blood test	25(OH)D	2 (2.7)	19 (26.7)	p<0.001
Treatment	Active vitamin D3 (%)	50 (67.6)	59 (79.7)	0.09
	SERM (%)	16 (21.6)	18 (24.3)	0.70
	Bisphosphonate (%)	54 (73.0)	39 (52.7)	0.11
	Denosumab (%)	5 (6.8)	6 (8.1)	0.75
	PTH preparation (%)	9 (12.2)	17 (23.0)	0.08
	Romosozumab (%)	0 (0)	3 (4.1)	0.08
	Vit K	2 (2.7)	0 (0)	0.15
Exercise therapy	Exercise therapy (%)	37 (50.0)	41 (55.4)	0.51
Nutritional guidance	Nutritional guidance (%)	26 (35.1)	32 (43.2)	0.31
Knowledge	Treatment experience (%)	43 (58.1)	40 (54.1)	0.62
	Guidelines (%)	25 (33.8)	24 (32.4)	0.86
	Lectures (%)	16 (21.6)	19 (26.7)	0.56
	Textbooks (%)	6 (8.1)	5 (6.8)	0.75
	Colleagues (%)	2 (2.7)	1 (1.4)	0.56
	Medical representative (%)	2 (2.7)	1 (1.4)	0.56
	No response (%)	0 (0)	2 (2.7)	0.15

Statistical analysis included a Chi-square test. Xp: X-ray photography; MRI: magnetic resonance imaging, NTX: type I collagen cross-linked N-telopeptide; BAP: alkaline phosphatase; P1NP: procollagen I N-terminal propeptide; TRACP-5b: tartrate-resistant acid phosphatase 5b; PTH: parathyroid hormone; ucOC: undercarboxylated osteocalcin; DPD: deoxypyridinoline. Duplicate responses were obtained.